These products may not have reliable dosing, sterility, purity, labeling, physician oversight, or pharmacy standards
Nausea, dizziness, and gastrointestinal symptoms are common with Wegovy, particularly during dose escalation
PMID 18599447
Dermatology studies show that using dangerous chemicals and bleaching your skin without following the rules could hurt your skin more than help it in the long run, leading to pigmentations
In the drugs best showing so far, the ATTAIN-1 trial, people taking orforglipron lost on average 12.4% of their baseline weight, a notch below the roughly 14% weight loss seen in similar trials of Novo Nordisks injectable Wegovy and also below the typical results seen with Eli Lillys tirzepatide, a dual GLP-1/GIP medication